Home › Research › Treatments
Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence
McLachlan DR, Fraser PE, Dalton AJ.. Ciba Foundation symposium, 1992-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Known risk factors for Alzheimer's disease (AD) are few and insufficient knowledge is available to recommend steps to reduce AD in our ageing populations. Although not 'the cause', considerable evidence implicates human ingestion of aluminium as a possible risk factor for the expression of dementia of the Alzheimer type. A recent epidemiological study in Ontario relating the incidence of AD to aluminium in drinking water strongly supports this conclusion. To test further the hypothesis that aluminium may play a role in the pathogenesis of AD we conducted a clinical trial employing the trivalent metal ion binding compound, desferrioxamine. The design was a two-year randomized trial with behavioural assessments blinded to study assignment. Sixty-three patients with probable AD were selected who were living at home and were under 74 years. Forty-eight signed an informed consent and completed all initial testing. The main outcome measure was a video-recorded home-behavioural assessment of measures of skills of daily living. The principal outcome was that the mean slope for performance of the skills of daily living for the group without treatment was -1.72% maximum score/month, compared to -0.87% maximum score/month for the group treated with desferrioxamine (P = 0.038). Considerable evidence supports the hypothesis that aluminium has an active role in the pathogenesis of AD.
What this study adds
Evidence grade: High
This is a trial. In this two-year randomized trial of 63 patients with probable Alzheimer's disease, those treated with desferrioxamine showed a slower decline in daily living skills than the untreated group. Reported effect size: 1.72%; 0.87%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
McLachlan, D. R., Fraser, P. E., & Dalton, A. J. (1992). Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence. Ciba Foundation symposium. https://doi.org/10.1002/9780470514306.ch6
Vancouver
McLachlan DR, Fraser PE, Dalton AJ. Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence. Ciba Foundation symposium. 1992. doi:10.1002/9780470514306.ch6. PMID: 1490430.
BibTeX
@article{mclachlan1992-1490430,
author = {McLachlan, D. R. and Fraser, P. E. and Dalton, A. J.},
title = {{Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence}},
journal = {Ciba Foundation symposium},
year = {1992},
doi = {10.1002/9780470514306.ch6},
pmid = {1490430},
url = {https://doi.org/10.1002/9780470514306.ch6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The principal outcome was that the mean slope for performance of the skills of daily living for the group without treatment was -1.72% maximum score/month, compared to -0.87% maximum score/month for the group treated with desferrioxamine (P = 0.038).
Why it matters
In this two-year randomized trial of 63 patients with probable Alzheimer's disease, those treated with desferrioxamine showed a slower decline in daily living skills than the untreated group. The authors argue that aluminium may play an active role in the disease process, though they note it is not 'the cause'.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Effect size1.72%; 0.87%
- Evidence strengthHigh
How this study scored 69/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 44 of the 64 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Ciba Foundation symposium) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1992 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (OpenAlex dates this DOI to 2007, the record says 1992; OpenAlex values not used) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 1490430) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 44 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 44 of the 64 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall and Europe PMC found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also in Treatments
201 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.